ADX-118

ADX-118 is a small molecule drug candidate developed by Addex Therapeutics. It is designed as a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 2 (mGluR2). The mGluR2 receptor is a G protein-coupled receptor that plays a significant role in modulating glutamate neurotransmission in the central nervous system. By enhancing the activity of mGluR2, ADX-118 aims to regulate excessive glutamate release, which is implicated in various neurological and psychiatric disorders. The primary indications explored for ADX-118 include schizophrenia and potentially other CNS-related conditions where glutamatergic dysfunction is a key component of the pathology.